

Supplementary materials

Contents

S1 – Full column CTAB protocol	1
S2 - Computer specifications for the computer used in this project	1
S3 - List of uploaded fastq files	1
S4 - Full basecalling comparison table	3
S5 - Full tuberculosis data analysis software comparison table	5
S6 - Full ONT vs Illumina concordance table	7

S1 – Full column CTAB protocol

500 µL of liquid culture or a loopful of solid culture was resuspended in 500 µL PBS in a 2 mL MPBio tube, heat killed, washed twice with PBS and resuspended in 100 µL TE buffer (10mM Tris pH8 and 1mM EDTA). 2 x 4 mm glass beads were added and the samples were vortexed for 45 seconds. 10 µL lysozyme (10 mg/mL) was added and the samples then incubated at 37°C for 15 minutes at 800 RPM. The samples were then transferred into 1.5 mL Eppendorf DNA LoBind tubes and 10 µL proteinase K and 3 µL RNase A added, provided with the NEB Monarch Genomic Purification Kit (T3010S, New England Biolabs). This was vortexed, 200 µL CTAB buffer (2% CTAB, 40mM EDTA, 1.4M NaCl and 100mM Tris pH8.0) added and vortexed again. The samples were incubated at 56°C for 30 minutes at 1000 RPM, then 100 µL 5M NaCl added. The tubes were centrifuged at 17,000 x *g* for 5 minutes and 200 µL of the supernatant retained, avoiding the pellet.

The Monarch Genomic Purification Kit manufacturer instructions were then followed, with these alterations: 400 µL gDNA binding buffer was added to the supernatant and vortexed for 10 seconds. The lysate/binding buffer mix was transferred to a gDNA purification column, centrifuged at 1,000 x *g* for 3 minutes and then maximum speed for 1 minute to clear the membrane. 500 µL gDNA wash buffer was added and centrifuged for 1 minute at maximum speed and then repeated. The gDNA purification column was then placed in a DNase-free 2.5 mL microfuge tube and 50-100 µL preheated 60°C gDNA elution buffer added. The tubes were incubated at room temperature for 1 minute and then centrifuged at maximum speed for 1 minute to elute the gDNA. DNA was eluted into 50 µL molecular grade water.

S2 - Computer specifications for the computer used in this project

Component Required	Specification
Operating system	Windows 10
Memory/RAM	32 GB RAM
CPU	Intel(R) Core(TM) i7-10700 CPU @ 2.90GHz 2.90 GHz
Storage	1 TB internal SSD
Ports	USB 3.0

S3 - List of uploaded fastq files

Isolate name	Sequencing platform	Sample Accession number	Experiment Accession number
TB_sensitive_1	Oxford Nanopore Technologies	ERS16613404	ERX11656854
TB_sensitive_2	Oxford Nanopore Technologies	ERS16613405	ERX11656855
TB_sensitive_3	Oxford Nanopore Technologies	ERS16613406	ERX11656856
TB_sensitive_4	Oxford Nanopore Technologies	ERS16613407	ERX11656857
TB_sensitive_5	Oxford Nanopore Technologies	ERS16613408	ERX11656858
TB_sensitive_6	Oxford Nanopore Technologies	ERS16613409	ERX11656859
TB_sensitive_7	Oxford Nanopore Technologies	ERS16613410	ERX11656860
TB_sensitive_8	Oxford Nanopore Technologies	ERS16613411	ERX11656861
TB_isoniazid_mono_1	Oxford Nanopore Technologies	ERS16613412	ERX11656845
TB_isoniazid_mono_2	Oxford Nanopore Technologies	ERS16613413	ERX11656846

TB_isoniazid_mono_3	Oxford Nanopore Technologies	ERS16613415	ERX11656847
TB_isoniazid_mono_4	Oxford Nanopore Technologies	ERS16613416	ERX11656848
TB_isoniazid_mono_5	Oxford Nanopore Technologies	ERS16613417	ERX11656849
TB_MDR_1	Oxford Nanopore Technologies	ERS16613418	ERX11656850
TB_MDR_2	Oxford Nanopore Technologies	ERS16613419	ERX11656851
TB_MDR_3	Oxford Nanopore Technologies	ERS16613420	ERX11656852
TB_MDR_4	Oxford Nanopore Technologies	ERS16613421	ERX11656853
TB_sensitive_1_1	Illumina	ERS16690010	ERX11656882
TB_sensitive_1_2	Illumina	ERS16690011	ERX11656883
TB_sensitive_2_1	Illumina	ERS16690012	ERX11656884
TB_sensitive_2_2	Illumina	ERS16690013	ERX11656885
TB_sensitive_3_1	Illumina	ERS16690014	ERX11656886
TB_sensitive_3_2	Illumina	ERS16690015	ERX11656887
TB_sensitive_4_1	Illumina	ERS16690016	ERX11656888
TB_sensitive_4_2	Illumina	ERS16690017	ERX11656889
TB_sensitive_5_1	Illumina	ERS16690018	ERX11656890
TB_sensitive_5_2	Illumina	ERS16690019	ERX11656891
TB_sensitive_6_1	Illumina	ERS16690020	ERX11656892
TB_sensitive_6_2	Illumina	ERS16690021	ERX11656893
TB_sensitive_7_1	Illumina	ERS16690022	ERX11656894
TB_sensitive_7_2	Illumina	ERS16690023	ERX11656895
TB_sensitive_8_1	Illumina	ERS16690024	ERX11656896
TB_sensitive_8_2	Illumina	ERS16690025	ERX11656897
TB_isoniazid_mono_1_1	Illumina	ERS16690026	ERX11656864
TB_isoniazid_mono_1_2	Illumina	ERS16690027	ERX11656865
TB_isoniazid_mono_2_1	Illumina	ERS16690028	ERX11656866
TB_isoniazid_mono_2_2	Illumina	ERS16690029	ERX11656867
TB_isoniazid_mono_3_1	Illumina	ERS16690030	ERX11656868
TB_isoniazid_mono_3_2	Illumina	ERS16690031	ERX11656869
TB_isoniazid_mono_4_1	Illumina	ERS16690032	ERX11656870
TB_isoniazid_mono_4_2	Illumina	ERS16690033	ERX11656871
TB_isoniazid_mono_5_1	Illumina	ERS16690034	ERX11656872
TB_isoniazid_mono_5_2	Illumina	ERS16690035	ERX11656873
TB_MDR_1_1	Illumina	ERS16690036	ERX11656874
TB_MDR_1_2	Illumina	ERS16690037	ERX11656875
TB_MDR_2_1	Illumina	ERS16690038	ERX11656876
TB_MDR_2_2	Illumina	ERS16690039	ERX11656877
TB_MDR_3_1	Illumina	ERS16690040	ERX11656878
TB_MDR_3_2	Illumina	ERS16690041	ERX11656879
TB_MDR_4_1	Illumina	ERS16690042	ERX11656880
TB_MDR_4_2	Illumina	ERS16690043	ERX11656881

S4 - Full basecalling comparison table

Sample	Basecaller	Lineage	Lineage name	Rifampicin	Isoniazid	Ethambutol	Streptomycin	Moxifloxacin	Ofloxacin	Amikacin	Capreomycin	Kanamycin	Pyrazinamide	Ethionamide	Ciprofloxacin	Fluoroquinolones	PAS	Cycloserine	Delamanid
S1	F	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S2	F	4.1.2.1	None	Se	Se	Se	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	4.1.2.1	T1	Se	Se	Se	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	4.1.2.1	T1	Se	Se	Se	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S3	F	4.1.1.1	X2	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	4.1.1.1	X2	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	4.1.1.1	X2	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S4	F	3	CAS	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	4.6	Manu2	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	4.6	Manu2	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S5	F	4.3.4	None	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	4.3.4.2	LAM9	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	4.3.4.2	LAM9	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S6	F	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	2.2.1	Beijing	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S7	F	4.1.3	None	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	

Sensitive

	H	4.1.3	T1	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	4.1.3	T1	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
S8	F	1.2.1.2.1	EAI2-nonthaburi	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	H	1.2.1.2.1	EAI2-nonthaburi	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se
	S	1.2.1.2.1	EAI2-nonthaburi	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se	Se

Isoniazid mono-resistant	I1	F	4.6.2.2	None	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		H	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		S	4.6.2.3	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
	I2	F	4.6.1.2	None	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	Se	Se	Se
		H	4.6.1.2	X1	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	gid c.102de1G	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	Se	Se	Se
		S	4.6.1.2	X1	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	gid c.102de1G	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T, inhA p.Ile194Thr	Se	Se	Se	Se
	I3	F	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		H	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		S	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
	I4	F	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		H	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		S	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
	I5	Fast	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		HAC	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se
		SUP	4.6.2.2	Cameroon	Se	fabG1 c.-15C>T	Se	Se	Se	Se	Se	Se	Se	Se	fabG1 c.-15C>T	Se	Se	Se	Se

MDR	M1	F	4.1.2.1	None	rpoB p.Ser450Leu	katG p.Ser315Thr	embB p.Met306Ile	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	pncA p.Leu85Pro	Se	Se	Se	Se	Se
		H	4.1.2.1	H1	rpoB p.Ser450Leu	katG p.Ser315Thr	embB p.Met306Ile	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	pncA p.Leu85Pro	Se	Se	Se	Se	Se
		S	4.1.2.1	H1	rpoB p.Ser450Leu	katG p.Ser315Thr	embB p.Met306Ile	rpsL p.Lys43Arg	Se	Se	Se	Se	Se	pncA p.Leu85Pro	Se	Se	Se	Se	Se

M2	F	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
	H	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
	S	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
M3	F	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
	H	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
	S	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	Se	Se	Se	Se	Se	Se	eis c.- 37G>T	Se	ethA c.-7T>C	Se	Se	Se	Se	Se
M4	F	4.2.1	Euro- American (TUR)	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	Se	rpsL p.Lys88Arg	Se	Se	Se	Se	Se	Se	Se	inhA c.-154G>A	Se	Se	Se	Se	Se
	H	4.2.1	Ural-1	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	Se	rpsL p.Lys88Arg	Se	Se	Se	Se	Se	Se	Se	inhA c.-154G>A	Se	Se	Se	Se	Se
	S	4.2.1	Ural-1	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	Se	rpsL p.Lys88Arg	Se	Se	Se	Se	Se	Se	Se	inhA c.-154G>A	Se	Se	Se	Se	Se

F=fast basecalling, H= high accuracy basecalling, S= super high accuracy basecalling, Se=sensitive

S5 - Full tuberculosis data analysis software comparison table

Sample	Software	Lineage	Lineage name	Rifampicin	Isoniazid	Ethambutol	Streptomycin	Moxifloxacin	Ofloxacin	Amikacin	Capreomycin	Kanamycin	Pyrazinamide	Ethionamide	Ciprofloxacin	Fluoroquinolones	PAS	Cycloserine	Delamanid
S1	T	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	M	2.2.10	n/a	S	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S2	T	4.1.2.1	T1	S	S	S	rpsL p.Lys43Arg	S	S	S	S	S	S	S	S	S	S	S	S
	M	4.1.2.1	n/a	S	S	S	rpsL p.Lys43Arg	S	S	S	S	S	S	NT	S	NT	NT	NT	NT

S3	T	4.1.1.1	X2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	4.1.1.1	n/a	S	S	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S4	T	4.6	Manu2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	3 and 4.6.2.2	n/a	S	C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S5	T	4.3.4	LAM9	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	4.3.4.2	n/a	S	S	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S6	T	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	2.2	n/a	S	S	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S7	T	4.1.3	T1	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	4.1.3	n/a	S	S	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
S8	T	1.2.1.2.1	EAI2-nonthaburi	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	
	M	1.2.1	n/a	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
I1	T	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.-15C>T	S	S	S	S	S
	M	4.6.2.2	n/a	S	C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
I2	T	4.6.1.2	X1	S	fabG1 c.-15C>T, inhA p.Ile194Thr	S	S	S	S	S	S	S	S	S	fabG1 c.-15C>T, inhA p.Ile194Thr	S	S	S	S	S
	M	4.6.1.2	n/a	S	inhA p.Ile194Thr C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
I3	T	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.-15C>T	S	S	S	S	S
	M	4.6.2.2	n/a	S	C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
I4	T	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.-15C>T	S	S	S	S	S
	M	4.6.2.2	n/a	S	C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
I5	T	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.-15C>T	S	S	S	S	S

Isoniazid mono resistance

	M	4.6.2.2	n/a	S	C in gene fabG1	S	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
MDR	M1	T	4.1.2.1	H1	rpoB p.Ser450Leu	katG p.Ser315Thr	M306I in gene embB	rpsL p.Lys43Arg	S	S	S	S	S	pncA p.Leu85Pro	S	S	S	S	S	S
		M	4.1.2.1	n/a	rpoB p.Ser450Leu	katG p.Ser315Thr	M306I in gene embB	rpsL p.Lys43Arg	S	S	S	S	S	pncA p.Leu85Pro	NT	S	NT	NT	NT	NT
	M2	T	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.-37G>T	S	ethA c.-7T>C	S	S	S	S	S
		M	2.2.10	n/a	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
	M3	T	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.-37G>T	S	ethA c.-7T>C	S	S	S	S	S
		M	2.2.10	n/a	S450L in gene rpoB	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT
	M4	T	4.2.1	Ural-1	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	S	rpsL p.Lys88Arg	S	S	S	S	S	S	inhA c.-154G>A	S	S	S	S	S
		M	4.2.1	n/a	S	katG p.Ser315Thr	S	S	S	S	S	S	S	S	NT	S	NT	NT	NT	NT

T= TB-Profiler, M= Mykrobe, S= sensitive, NT = not tested

S6 - Full ONT vs Illumina concordance table

		Lineage	Lineage name	Rifampicin	Isoniazid	Ethambutol	Streptomycin	Moxifloxacin	Ofloxacin	Amikacin	Capreomycin	Kanamycin	Pyrazinamide	Ethionamide	Ciprofloxacin	Fluoroquinolones	PAS	Cycloserine	Delaminid
Sensitive	S1	P	n/a	n/a	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
		O	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
		I	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	S2	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT

	O	4.1.2.1	T1	S	S	S	rpsL p.Lys43Arg	S	S	S	S	S	S	S	S	S	S	S	S
	I	4.1.2.1	T1	S	S	S	rpsL p.Lys43Arg	S	S	S	S	S	S	S	S	S	S	S	S
S3	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.1.1.1	X2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	4.1.1.1	X2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
S4	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	3 and 4.6	CAS, Manu2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	3	CAS1-Delhi	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
S5	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.3.4	LAM9	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	4.3.4.2	LAM9	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
S6	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	2.2.1	Beijing	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
S7	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.1.3	T1	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	4.1.3	T1	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
S8	P	n/a	n/a	S	S	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	1.2.1.2.1	EAI2- nonthaburi	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
	I	1.2.1.2.1	EAI2- nonthaburi	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Isoniazid mono	P	n/a	n/a	S	R	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S
	I	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S

I2	P	n/a	n/a	S	R	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.6.1.2	X1	S	fabG1 c.-15C>T, inhA p.Ile194Thr	S	gid c.102de1G	S	S	S	S	S	S	fabG1 c.- 15C>T, inhA p.Ile194Thr	S	S	S	S	S
	I	4.6.1.2	X1	S	fabG1 c.-15C>T, inhA p.Ile194Thr	S	gid c.102delG	S	S	S	S	S	S	fabG1 c.- 15C>T, inhA p.Ile194Thr	S	S	S	S	S
I3	P	n/a	n/a	S	R	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
	I	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
I4	P	n/a	n/a	S	R	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
	I	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
I5	P	n/a	n/a	S	R	S	S	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
	O	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
	I	4.6.2.2	Cameroon	S	fabG1 c.-15C>T	S	S	S	S	S	S	S	S	fabG1 c.- 15C>T	S	S	S	S	S
MDR	M1	P	n/a	n/a	R	R	S	R	NT	NT	NT	NT	NT	R	NT	NT	NT	NT	NT
		O	4.1.2.1	H1	rpoB p.Ser450Leu	katG p.Ser315Thr	embB p.Met306Ile	rpsL p.Lys43Arg	S	S	S	S	S	pncA p.Leu85Pro	S	S	S	S	S
		I	4.1.2.1	H1	rpoB p.Ser450Leu	katG p.Ser315Thr	embB p.Met306Ile	rpsL p.Lys43Arg	S	S	S	S	S	pncA p.Leu85Pro	S	S	S	S	S
M2	P	n/a	n/a	R	R	S	R	NT	NT	NT	NT	NT	R	NT	NT	NT	NT	NT	NT
	O	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.- 37G>T	S	ethA c.-7T>C	S	S	S	S	S
	I	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.- 37G>T	S	ethA c.-7T>C	S	S	S	S	S
M3	P	n/a	n/a	R	R	S	S	NT	NT	NT	NT	NT	R	NT	NT	NT	NT	NT	NT
	O	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.- 37G>T	S	ethA c.-7T>C	S	S	S	S	S

	I	2.2.1	Beijing	rpoB p.Ser450Leu, rpoB p.Glu761Asp	katG p.Ser315Thr	embB p.Asp354Ala	S	S	S	S	S	eis c.- 37G>T	S	ethA c.-7T>C	S	S	S	S	S
	P	n/a	n/a	R	R	S	R	NT	NT	NT	NT	NT	S	NT	NT	NT	NT	NT	NT
	O	4.2.1	Ural-1	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	S	rpsL p.Lys88Arg	S	S	S	S	S	S	inhA c.- 154G>A	S	S	S	S	S
I	4.2.1	Ural-1	rpoB p.Ser450Leu, rpoC p.Asp485Asn	inhA c.-154G>A, katG p.Ser315Thr	S	rpsL p.Lys88Arg	S	S	S	S	S	S	inhA c.- 154G>A	S	S	S	S	S	

P = phenotypic, O = Oxford Nanopore Technologies WGS, I = Illumina WGS, NT = Not tested, R = resistant, S = sensitive. Only resistance mutations of final confidence grading of ≥ 3 according to the WHO's Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance.